Delving into the Latest Updates on TransPharma Medical Ltd. with Synapse

Overview

The primary purpose of this study is to help answer the following research questions:
How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are).
The safety of the teriparatide skin patch and any side effects that might be associated with it.

Start Date01 Nov 2009

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

NCT00535860 / CompletedPhase 2

A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis

The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in postmenopausal women with Osteoporosis

Start Date01 Apr 2008

Sponsor / Collaborator

TransPharma Medical Ltd.

[+1]

EUCTR2007-004633-41-HU / Not yet recruitingNot Applicable

A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) (Double-Blinded for 2 Different Dosages) in Comparison to Subcutaneous Injection of Forteo? Following 3-Month Treatment in Postmenopausal Women with Osteoporosis and Osteopenia

Start Date04 Dec 2007

Sponsor / Collaborator

TransPharma Medical Ltd.

100 Clinical Results associated with TransPharma Medical Ltd.

Login to view more data

0 Patents (Medical) associated with TransPharma Medical Ltd.

Login to view more data

2

Literatures (Medical) associated with TransPharma Medical Ltd.

01 Jan 2012·Pharmacology &amp; Pharmacy

Radio Frequency-Microchannels for Transdermal Delivery: Characterization of Skin Recovery and Delivery Window

Author: Kam, Yossi ; Levin, Galit ; Stern, Meir ; Sacks, Hagit ; Kaplan, Keren Mevorat

Transdermal delivery through Radio-Frequency-MicroChannels (RF-MCs) was proven to be a promising delivery method for hydrophilic drugs and macromols. that must be injected.An important issue in assessing this technol. is the life span of the microchannels (MCs).The time window in which the MCs remain open affects the delivery rate and determine the effective delivery duration.The present work focused on the characterization of the ViaDor-MCs recovery and closure process by measurements of transepidermal water loss (TEWL) before and after the formation of MCs, evaluation of the delivery window, and assessment of skin histol.Testosterone-cyclodextrin complex was used as the model drug for evaluation of the transdermal delivery.In-vitro permeation system and in-vivo guinea pig animal model were used in the delivery studies.Our findings demonstrate the recovery process of MCs created by the RF ablation technol.The observed gradual skin recovery affected the transdermal delivery rate.A significant transdermal delivery was shown up to 24 h post device application suggesting that an extended delivery of water soluble drugs, including macromols., is possible.The histol. assessments demonstrated repair and healing of the induced MCs indicating that the RF micro-channeling technol. is minimally invasive, transient in nature with no resulting skin trauma.

Pharmaceutical Technology

Advances in radio-frequency transdermal drug delivery

Author: Levin, Galit

A review.A microelectronic system based on radio-frequency (RF) cell ablation addresses limitations of other transdermal drug-delivery methods.This system expands the transdermal spectrum to include the delivery of water-soluble mols., peptides, proteins, and other macromols.The author discusses the technol. and its benefits.

1

News (Medical) associated with TransPharma Medical Ltd.

08 May 2006

·www.biospace.com

TransPharma Medical Ltd. Receives First Milestone Payment From TEVA Pharmaceuticals

TransPharma-Medical Ltd., the Israeli-based biopharmaceutical company that develops pharmaceutical products utilizing its unique transdermal RF-MicroChannels™ transdermal drug delivery technology , announces today it has received its first milestone payment from Teva Pharmaceuticals for successfully completing the first clinical trials, based on a joint development agreement originally signed between the two companies in 2004.

100 Deals associated with TransPharma Medical Ltd.

Login to view more data

100 Translational Medicine associated with TransPharma Medical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Insulin transdermal(TransPharma Medical Ltd.) ( INSR )	Diabetes Mellitus, Type 2 More	Discontinued
Teriparatide(Eli Lilly) ( PTH1R )	Osteoporosis More	Pending
ViaDor-GLP1 agonist(TransPharma Medical) ( GLP-1R )	Diabetes Mellitus, Type 2 More	Pending